Company file
keyboard_backspaceBack to directoryIdentity
Lysogene
Lysogene is a biopharmaceutical gene therapy company, founded in 2009, with lead programs in neurodegenerative lysosomal storage disorders that affect children. Lysogene uses recombinant adeno-associated virus (AAV) that specifically targets neural cells and is administered directly into the brain or cerebrospinal fluid (CSF).
Contact
18 Rue Jacques Dulud
92200 Neuilly-sur-Seine
France
01.41.43.03.90
Activities
- Research structure
- Gene Delivery system
- Adeno-Associated Virus (AAV)
- Bioproduction
- Bioproduction
- Scale-Up
- Automate manufacturing
- Automated high-throughput microbioreactor system
- Supply chain logistics
- Tracking process
- Monitoring logistics
- Non-GMP pilot batch
- GMP batch
- Ex Vivo & In Vivo Strategy
- Ex Vivo & In Vivo Strategy
- Cell modification
- Gene modification
